-
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
31 May 2025 12:00 GMT
… diagnosed with metastatic pancreatic adenocarcinoma, the most important question … patients with metastatic pancreatic adenocarcinoma. Ipsen has exclusive commercialization … with metastatic pancreatic ductal adenocarcinoma (mPDAC): final overall survival …
-
‘Spread Through Air Spaces’ Predicts Poorer Prognosis in Stage 1 EGFR-Mutant Lung Adenocarcinoma
29 May 2025 23:35 GMT
… factor receptor-mutated (EGFRm) lung adenocarcinoma. The findings were presented during … patients with stage 1 lung adenocarcinoma and a minimum of three …
-
US FDA grants fast track designation to EDDC's antibody─drug conjugate EBC─129 to treat pancreatic ductal adenocarcinoma
29 May 2025 07:00 GMT
… the treatment of pancreatic ductal adenocarcinoma (PDAC). EBC-129 is a … ), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 … recruitment continues for the gastroesophageal adenocarcinoma (GEA) and IHC-positive cohorts …
-
Treatment of Inoperable Pancreatic Adenocarcinoma with Focused Ultrasound and Microbubbles in Patients Receiving Chemotherapy
28 May 2025 22:09 GMT
… patients with inoperable pancreatic ductal adenocarcinoma (PDAC) and to investigate safety …
-
First-Line Treatment Options for Metastatic Pancreatic Adenocarcinoma
28 May 2025 16:24 GMT
… therapy options for metastatic pancreatic adenocarcinoma. Dr. Chandana, a GI medical … frontline therapy in metastatic pancreatic adenocarcinoma. The two physicians plan to … for first-line metastatic pancreatic adenocarcinoma therapy.
Dr. Shah explains that …
-
Insights From The NAPOLI-3 and PRODIGE4 Trials In Metastatic Pancreatic Adenocarcinoma
28 May 2025 16:24 GMT
… treatment approaches for metastatic pancreatic adenocarcinoma. The NAPOLI-3 study led … treatment option for metastatic pancreatic adenocarcinoma. In contrast, the PRODIGE 4 …
-
Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma
28 May 2025 08:29 GMT
… unmet needs in pancreatic ductal adenocarcinoma (PDAC).
Updated clinical data … recruitment continues for the gastroesophageal adenocarcinoma (GEA) and IHC-positive … 129-to-treat-pancreatic-ductal-adenocarcinoma-302465707.html
SOURCE EXPERIMENTAL DRUG …
-
Community celebrates 25 years of Miles Perret Cancer Services in Lafayette
01 Jun 2025 00:30 GMT
… in 2007 and later with adenocarcinoma in 2012, she knows the …
-
Dr Picozzi on the Addition of TTFields to Gemcitabine and Nab-Paclitaxel in Locally Advanced PDAC
01 Jun 2025 00:24 GMT
… with locally advanced pancreatic ductal adenocarcinoma (PDAC).
Results from PANOVA-3 …
-
Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
31 May 2025 20:47 GMT
… gastric or gastroesophageal junction (GEJ) adenocarcinoma that expresses CLDN18.2. While … testing in gastric and GEJ adenocarcinoma. Early this year, ArriVent Biopharma …
About
© 1995-2025